160 related articles for article (PubMed ID: 34655958)
1. Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients.
Baharnoori M; Wilson R; Saxena S; Gonzalez CT; Sotiropoulos MG; Keyhanian K; Healy BC; Chitnis T
Mult Scler Relat Disord; 2021 Nov; 56():103311. PubMed ID: 34655958
[TBL] [Abstract][Full Text] [Related]
2. Adipokines are associated with pediatric multiple sclerosis risk and course.
Keyhanian K; Saxena S; Gombolay G; Healy BC; Misra M; Chitnis T
Mult Scler Relat Disord; 2019 Nov; 36():101384. PubMed ID: 31550559
[TBL] [Abstract][Full Text] [Related]
3. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
4. Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients.
Sánchez-Sanz A; García-Martín S; Sabín-Muñoz J; Moreno-Torres I; Elvira V; Al-Shahrour F; García-Grande A; Ramil E; Rodríguez-De la Fuente O; Brea-Álvarez B; García-Hernández R; García-Merino A; Sánchez-López AJ
Front Immunol; 2023; 14():1209923. PubMed ID: 37483622
[TBL] [Abstract][Full Text] [Related]
5. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
Nicholas JA; Boster AL; Imitola J; O'Connell C; Racke MK
Drug Des Devel Ther; 2014; 8():897-908. PubMed ID: 25045248
[TBL] [Abstract][Full Text] [Related]
6. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
[TBL] [Abstract][Full Text] [Related]
7. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
Miclea A; Leussink VI; Hartung HP; Gold R; Hoepner R
J Neurol; 2016 Aug; 263(8):1626-32. PubMed ID: 27260297
[TBL] [Abstract][Full Text] [Related]
10. Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis.
Traub J; Traffehn S; Ochs J; Häusser-Kinzel S; Stephan S; Scannevin R; Brück W; Metz I; Weber MS
Brain Pathol; 2019 Sep; 29(5):640-657. PubMed ID: 30706542
[TBL] [Abstract][Full Text] [Related]
11. Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses.
Wipke BT; Hoepner R; Strassburger-Krogias K; Thomas AM; Gianni D; Szak S; Brennan MS; Pistor M; Gold R; Chan A; Scannevin RH
Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33468560
[TBL] [Abstract][Full Text] [Related]
12. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
[TBL] [Abstract][Full Text] [Related]
13. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies.
Montes Diaz G; Hupperts R; Fraussen J; Somers V
Autoimmun Rev; 2018 Dec; 17(12):1240-1250. PubMed ID: 30316988
[TBL] [Abstract][Full Text] [Related]
14. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.
Diebold M; Sievers C; Bantug G; Sanderson N; Kappos L; Kuhle J; Lindberg RLP; Derfuss T
J Autoimmun; 2018 Jan; 86():39-50. PubMed ID: 28958667
[TBL] [Abstract][Full Text] [Related]
15. Adipokines in multiple sclerosis patients are related to clinical and radiological measures.
Loonstra FC; Falize KF; de Ruiter LRJ; Schoonheim MM; Strijbis EMM; Killestein J; de Vries HE; Uitdehaag BMJ; Rijnsburger M
J Neurol; 2023 Apr; 270(4):2018-2030. PubMed ID: 36562851
[TBL] [Abstract][Full Text] [Related]
16. Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis.
Hosseini A; Masjedi A; Baradaran B; Hojjat-Farsangi M; Ghalamfarsa G; Anvari E; Jadidi-Niaragh F
J Cell Physiol; 2019 Jul; 234(7):9943-9955. PubMed ID: 30536402
[TBL] [Abstract][Full Text] [Related]
17. Dimethyl fumarate downregulates the immune response through the HCA
von Glehn F; Dias-Carneiro RPC; Moraes AS; Farias AS; Silva VAPG; Oliveira FTM; Silva CEBG; de Carvalho F; Rahal E; Baecher-Allan C; Santos LMB
Mult Scler Relat Disord; 2018 Jul; 23():46-50. PubMed ID: 29763776
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.
Montes Diaz G; Fraussen J; Van Wijmeersch B; Hupperts R; Somers V
Sci Rep; 2018 May; 8(1):8194. PubMed ID: 29844361
[TBL] [Abstract][Full Text] [Related]
19. Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review.
Suneetha A; Raja Rajeswari K
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1019():15-20. PubMed ID: 26899449
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP
Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
